OKRA.ai, a provider of Artificial Intelligence (AI) driven analytics for global life sciences, today announced that it is extending its collaboration with Bristol Myers Squibb to leverage OKRA’s AI Technology to support future customer engagement. This collaboration, which started in the UK in 2018 has proven to be very successful in bringing together multiple data sources and generating intelligent insights for commercial teams whilst delivering unparalleled levels of automation for the company. In 2021 OKRA.ai and Bristol Myers Squibb expanded use of the system to new markets and will continue to work together and explore further expansion opportunities in 2022.
Read more about the collaboration here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.